Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) had its target price decreased by stock analysts at HC Wainwright from $27.00 to $18.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's target price suggests a potential upside of 195.08% from the company's current price.
Several other research analysts also recently weighed in on the company. Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. JMP Securities reiterated a "market outperform" rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $17.25.
Read Our Latest Stock Report on Enanta Pharmaceuticals
Enanta Pharmaceuticals Price Performance
Shares of NASDAQ ENTA traded down $0.27 during midday trading on Tuesday, reaching $6.10. The company's stock had a trading volume of 241,835 shares, compared to its average volume of 225,231. The stock has a market capitalization of $129.28 million, a P/E ratio of -1.11 and a beta of 0.49. The firm has a 50 day moving average price of $9.64 and a 200-day moving average price of $11.66. Enanta Pharmaceuticals has a 12-month low of $5.70 and a 12-month high of $17.80.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. During the same period in the prior year, the company earned ($1.33) earnings per share. The firm's revenue was down 22.8% on a year-over-year basis. On average, equities analysts predict that Enanta Pharmaceuticals will post -4.73 EPS for the current year.
Insiders Place Their Bets
In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.64% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its holdings in shares of Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company's stock worth $958,000 after buying an additional 8,645 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at about $35,000. Rhumbline Advisers boosted its holdings in shares of Enanta Pharmaceuticals by 4.7% in the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock worth $448,000 after purchasing an additional 1,548 shares in the last quarter. Quest Partners LLC increased its position in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $150,000 after purchasing an additional 9,692 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock valued at $362,000 after buying an additional 7,287 shares in the last quarter. Institutional investors own 94.99% of the company's stock.
Enanta Pharmaceuticals Company Profile
(
Get Free Report)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Further Reading
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
